Canadian Cancer Clinical Trials Network

Canadian Cancer Clinical Trials Network
Name	Canadian Cancer Clinical Trials Network
Formation	20XX
Type	Non-profit network
Headquarters	Toronto, Ontario
Region served	Canada
Leader title	Executive Director

Canadian Cancer Clinical Trials Network is a national consortium coordinating oncology clinical trials across provinces, linking institutions, investigators, funders, regulatory bodies, and patient advocacy groups. The Network connects major hospitals, research institutes, and academic centres to harmonize trial design, accelerate regulatory submissions, and expand access to experimental therapies for rare and common malignancies. It supports translational oncology, precision medicine, and population-based studies by integrating infrastructure from clinical research centres, biobanks, and data platforms.

History and Establishment

The Network emerged from dialogues among stakeholders including Canadian Institutes of Health Research, Cancer Care Ontario, BC Cancer, Alberta Health Services, McGill University Health Centre, Princess Margaret Cancer Centre, and representatives from provincial ministries and national charities. Early planning convened leaders from CIHR Institute of Cancer Research, Canadian Cancer Society, Institut national de santé publique du Québec, Nova Scotia Health Authority, and academic groups such as University of Toronto, McMaster University, University of British Columbia, and Université de Montréal. Founding meetings referenced models like NIH, National Cancer Institute (US), European Organisation for Research and Treatment of Cancer, and UK National Institute for Health and Care Research to adapt multinational best practices. The formal launch followed consultations with regulatory agencies including Health Canada and ethical bodies like Tri-Council Policy Statement committees, alongside patient representatives from Canadian Cancer Survivor Network and clinical leaders from Saskatchewan Cancer Agency and CancerCare Manitoba.

Governance and Organizational Structure

Governance includes a board with representatives from academic centres such as Dalhousie University, Queen's University, Western University, and University of Calgary, alongside members from research organizations like MaRS Discovery District, Ontario Institute for Cancer Research, SickKids Research Institute, and community charities like Canadian Cancer Society. Executive operations coordinate with clinical trial offices at Vancouver General Hospital, St. Michael's Hospital, Sunnybrook Health Sciences Centre, and provincial research networks including Alberta Innovates and Saskatchewan Health Research Foundation. Scientific advisory committees draw expertise from investigators affiliated with The Ottawa Hospital Research Institute, BC Cancer Research Centre, Lunenfeld-Tanenbaum Research Institute, and international advisors from MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Gustave Roussy. Ethics oversight aligns with institutional review boards at McGill University Health Centre, Hamilton Health Sciences, and patient engagement panels representing groups like Colorectal Cancer Canada and Lymphoma Canada.

Clinical Trial Programs and Services

Programs span phase I–III oncology trials, investigator-initiated studies, and translational research embedded in centres such as Princess Margaret Cancer Centre, BC Cancer Centre for Drug Development, and Ottawa Hospital Cancer Centre. Services include trial startup facilitation with clinical trial units at Sunnybrook Odette Cancer Centre, centralized pharmacy support linking to Toronto General Hospital, and imaging core labs cooperating with Juravinski Cancer Centre and London Health Sciences Centre. The Network supports biomarker-driven protocols with biobanks at Ontario Cancer Institute, genomics pipelines connected to Canadian Centre for Computational Genomics, and companion diagnostics developed with partners like Illumina collaborators and diagnostic laboratories at Mount Sinai Hospital (Toronto). Patient recruitment and outreach utilize registries and advocacy groups such as Princess Margaret Patient and Family Advisory Council and provincial screening programs like Alberta Cancer Screening Program.

Research Collaborations and Partnerships

Collaborations span academic consortia including Translational Research Program, cooperative groups like Canadian Cancer Trials Group, industry partners ranging from multinational pharmaceutical companies to biotech startups incubated at MaRS Discovery District and JLABS. International research links involve European Society for Medical Oncology, American Society of Clinical Oncology, International Agency for Research on Cancer, and multicentre collaborations with institutions like University College London and Karolinska Institutet. Partnerships with population health organizations include Statistics Canada data linkages, linkage projects with provincial cancer registries at Ontario Cancer Registry, and clinical informatics initiatives integrated with Canadian Primary Care Sentinel Surveillance Network nodes. Training and capacity building occur with programs at CIHR, CanVECTOR, and professional societies including Canadian Association of Medical Oncologists and Canadian Association of Radiation Oncology.

Funding and Sustainability

Funding sources include peer-reviewed grants from Canadian Institutes of Health Research, infrastructure investments from provincial ministries such as Ontario Ministry of Health and philanthropic contributions from Canadian Cancer Society and private foundations like Princess Margaret Cancer Foundation. Collaborative industry partnerships bring sponsored research agreements with biotechnology firms and pharmaceutical companies, complemented by in-kind support from academic hospitals like Mount Sinai Hospital (Toronto), St. Joseph's Health Centre (Toronto), and research networks including CanCertainty. Financial oversight involves budgeting practices aligned with standards from Canadian Institute for Health Information and audits coordinated with entities such as Auditor General of Ontario where applicable. Sustainability strategies include endowment models coordinated with university partners and philanthropic campaigns conducted with organizations like Sunnybrook Foundation.

Impact, Outcomes, and Publications

The Network's outputs include multicentre trial results published in journals such as The Lancet Oncology, Journal of Clinical Oncology, Nature Medicine, JAMA Oncology, and Cancer Research. Outcomes feature improved accrual rates at participating sites including Princess Margaret Cancer Centre and BC Cancer, faster ethics approvals in collaboration with institutional boards at McGill University, and enhanced access to novel agents developed with partners like Novartis and Roche. Bibliometric impact is measured via citations in systematic reviews by Cochrane Collaboration and guidelines influenced by bodies including NCCN and ASCO. Public dissemination occurs through conferences such as ASCO Annual Meeting, ESMO Congress, Canadian Cancer Research Conference, and provincial symposia hosted by Cancer Care Ontario and BC Cancer.

Category:Cancer research organizations in Canada